SUPN
Supernus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$43.53
−1.00%Aug 31, 2026, 12:30 UTC
Supernus Pharmaceuticals announced a compensated ambassador partnership with professional snowboarder Chloe Kim to discuss her ADHD journey and treatment with Qelbree.
Source:Aug 13, 2026, 07:38 UTC
Assenagon Asset Management S.A. reduced its stake in Supernus Pharmaceuticals, Inc. by 86.2% during the quarter, selling 457,443 shares and retaining 73,175 shares, as disclosed in a 13F filing.
Source:Aug 7, 2026, 16:00 UTC
Kahn Swick & Foti, LLC announced an investigation into the adequacy of the price and process in the proposed sale of Supernus Pharmaceuticals, Inc.
Source:Aug 3, 2026, 10:35 UTC
Supernus Pharmaceuticals announced its financial results for the second quarter of 2026.
Source:Aug 3, 2026, 10:30 UTC
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a definitive agreement to merge in an all-stock merger of equals, creating a combined CNS biopharmaceutical company named Supernus, Inc.
Jun 17, 2026, 14:15 UTC
MERGE was selected as the Agency of Record for Supernus Pharmaceuticals, expanding their partnership to unify digital marketing and technology platforms.